The efficacy and safety of rabbit anti-thymocyte globulin vs rabbit anti-T-lymphocyte globulin in peripheral blood stem cell transplantation from unrelated donors

References

• Arora M, Weisdorf DJ, Spellman SR, et al. HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. J Clin Oncol 2009;27:1644–1652.
   PubMed Web of Science ®Google Scholar
• Weisdorf DJ, Anasetti C, Antin JH, et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 2002;99:1971–1977.
   PubMed Web of Science ®Google Scholar
• Sirinoglu Demiriz I, Tekgunduz E, Altuntas F. What is the most appropriate source for hematopoietic stem cell transplantation? Peripheral stem cell/bone marrow/cord blood.. Bone Marrow Res 2012;2012:834040.
   PubMedGoogle Scholar
• Anasetti C, Logan BR, Lee SJ, et al. Blood and Marrow Transplant Clinical Trials Network. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012;367: 1487–1496.
   PubMed Web of Science ®Google Scholar
• Gaber AO, Monaco AP, Russell JA, et al. Rabbit antithymocyte globulin (thymoglobulin): 25 years and new frontiers in solid organ transplantation and haematology. Drugs 2010;70:691–732.
   PubMed Web of Science ®Google Scholar
• Kumar A, Mhaskar AR, Reljic T, et al. Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review. Leukemia 2012;26:582–588.
   PubMed Web of Science ®Google Scholar
• Sheng Z, Ma H, Pang W, et al. In vivo T-cell depletion with antithymocyte globulins improves overall survival after myeloablative allogeneic stem cell transplantation in patients with hematologic disorders. Acta Haematol 2013;129:146–153.
   PubMed Web of Science ®Google Scholar
• Ayuk F, Maywald N, Hannemann S, et al. Comparison of the cytotoxicity of 4 preparations of anti-T-cell globulins in various hematological malignancies. Anticancer Res 2009;29:1355–1360.
   PubMed Web of Science ®Google Scholar
• Preville X, Nicolas L, Flacher M, et al. A quantitative flow cytometry assay for the preclinical testing and pharmacological monitoring of rabbit antilymphocyte globulins (rATG). J Immunol Methods 2000;245:45–54.
   PubMed Web of Science ®Google Scholar
• Penack O, Fischer L, Gentilini C, et al. The type of ATG matters – natural killer cells are influenced differentially by Thymoglobulin, Lymphoglobulin and ATG-Fresenius. Transpl Immunol 2007;18:85–87.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Min WS, Cho BS, et al. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2009;15:704–717.
   PubMed Web of Science ®Google Scholar
• Ayuk F, Diyachenko G, Zabelina T, et al. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors. Exp Hematol 2008;36:1047–1054.
   PubMed Web of Science ®Google Scholar
• Basara N, Baurmann H, Kolbe K, et al. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplant 2005;35:1011–1018.
   PubMed Web of Science ®Google Scholar
• Remberger M, Svahn BM, Hentschke P, et al. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant 1999;24:823–830.
   PubMed Web of Science ®Google Scholar
• Schleuning M, Kaltenhäuser J, Heshmat M, et al. The influence of ATG source on the outcome after unrelated transplants for chronic phase CML – a single-centre experience. Bone Marrow Transplant 2004;33:O357.
   Google Scholar
• Huang W, Li H, Gao C, et al. Unmanipulated HLA-mismatched/haploidentical peripheral blood stem cell transplantation for high-risk hematologic malignancies. Transfusion 2012;52:1354–1362.
   PubMed Web of Science ®Google Scholar
• Sullivan KM. Graft-versus-host disease. In: Blume KG, Forman SJ, Appelbaum FR, editors. Thomas’ Hematopoietic Cell Transplantation. 3rd ed. Malden, MA: Blackwell Publishing Ltd; 2004. p 633–664.
   Google Scholar
• National Cancer Institute Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Data files and related documents. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/About.html. Accessed 24 January 2013.
   Google Scholar
• Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004;104:1923–1930.
   PubMed Web of Science ®Google Scholar
• Cheuk DK. Optimal stem cell source for allogeneic stem cell transplantation for hematological malignancies. World J Transplant 2013;3:99–112.
   PubMedGoogle Scholar
• Pidala J. Graft-vs-host disease following allogeneic hematopoietic cell transplantation. Cancer Control 2011;18:268–2676.
   PubMed Web of Science ®Google Scholar
• Remberger M, Storer B, Ringden O, et al. Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant 2002;29:391–397.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001;98:2942–2947.
   PubMed Web of Science ®Google Scholar
• Storb R, Gyurkocza B, Storer BE, et al. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol 2013;31:1530–1538.
   PubMed Web of Science ®Google Scholar
• Duggan P, Booth K, Chaudhry A, et al. Alberta Blood and Bone Marrow Transplant Program. Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis. Bone Marrow Transplant 2002;30:681–686.
   PubMed Web of Science ®Google Scholar
• Kröger N, Zabelina T, Krüger W, et al. In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. Bone Marrow Transplant 2002;29:683–689.
   PubMed Web of Science ®Google Scholar
• Finke J, Bethge WA, Schmoor C, et al. ATG - Fresenius Trial Group. Standard graft-versu-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009;10:855–864.
   PubMed Web of Science ®Google Scholar
• Remberger M, Svahn BM, Mattsson J, et al. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation 2004;78:122–127.
   PubMed Web of Science ®Google Scholar
• Duval M, Pédron B, Rohrlich P, et al. Immune reconstitution after haematopoietic transplantation with two different doses of pre-graft antithymocyte globulin. Bone Marrow Transplant 2002; 30:421–426.
   PubMed Web of Science ®Google Scholar
• Meijer E, Cornelissen JJ, Lowenberg B, et al. Antithymocyteglobulin as prophylaxis of graft failure and graft-versus-host disease in recipients of partially T-cell-depleted grafts from matched unrelated donors: a dose-finding study. Exp Hematol 2003;31:1026–1030.
   PubMed Web of Science ®Google Scholar
• Schleuning M, Gunther W, Tischer J, et al. Dose-dependent effects of in vivo antithymocyte globulin during conditioning for allogeneic bone marrow transplantation from unrelated donors in patients with chronic phase CML. Bone Marrow Transplant 2003;32:243–250.
   PubMed Web of Science ®Google Scholar
• Fan Z, Yi Z, Liu Q, et al. Quadruple therapy with CsA, MTX, MMF and ATG and triple therapy with CsA, MTX and ATG for preventing graft-versus-host disease in unrelated donor hematopoietic stem cell transplantation. Blood 2005;106 (Suppl): Abstract 5296.
   Google Scholar
• Jagasia M, Arora M, Flowers ME, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012;119:296–307.
   PubMed Web of Science ®Google Scholar
• Ayuk F, Diyachenko G, Zabelina T, et al. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008;14:913–919.
   PubMed Web of Science ®Google Scholar
• Pihusch R, Holler E, Mühlbayer D, et al. The impact of antithymocyte globulin on short-term toxicity after allogeneic stem cell transplantation. Bone Marrow Transplant 2002;30:347–354.
   PubMed Web of Science ®Google Scholar
• Waller EK, Langston AA, Lonial S, et al. Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 2003;9:460–471.
   PubMed Web of Science ®Google Scholar
• Pidala J, Tomblyn M, Nishihori T, et al. ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011;17:1237–1244.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Lamparelli T, Barisione G, et al. Gruppo Italiano Trapianti Midollo Osseo (GITMO). Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006;12:560–565.
   PubMed Web of Science ®Google Scholar